Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs
Lan Juan Li,Wei Bo Du,Yi Min Zhang,Jun Li,Xiao Ping Pan,Jia Jia Chen,Hong Cui Cao,Yu Chen,Yue Mei Chen
DOI: https://doi.org/10.1016/j.jhep.2005.08.006
IF: 25.7
2006-01-01
Journal of Hepatology
Abstract:Methods FHF was induced with intravenous administration of D -galactosamine (1.3 g/kg) in each pig. Twelve hours post D -galactosamine injection, fifteen pigs were divided into: a BAL group ( n =5), in which pigs received the BAL treatment with 1.0 to 1.3×10 9 hepatocytes for 6 h, a sham BAL group ( n =5), in which pigs received the BAL treatment without hepatocytes, and a FHF group ( n =5), in which pigs only received intensive care. Parameters related to liver function and animal survival up to 168 h were determined. Results In the BAL group, blood ammonia and plasma lactate levels were lower, and serum glucose levels and Fischer index were higher than those in the other two groups. Survival time of pigs in the BAL group was significantly prolonged as compared with the sham BAL and the FHF group. Conclusions The BAL based on a nonwoven fabric bioreactor containing porcine hepatocytes appears to be effective in the treatment of FHF in pigs. Keywords Hepatic failure Bioartificial liver Hepatocyte Bioreactor Nonwoven fabric D -galactosamine Pig 1 Introduction Despite recent considerable improvements in supportive therapy, fulminant hepatic failure (FHF) remains a dramatic disease which is associated with a high mortality rate [1–3] . Orthotopic liver transplantation is the ultimate treatment for FHF [4–9] . However, numerous patients died while waiting for a transplant due to persistent scarcity of donors [10,11] . In such a situation, a bioartificial liver (BAL) may improve survival by bridging patients to liver transplantation or to regeneration of their diseased livers [12–17] . Currently, several BAL systems based on hollow fiber technology have been in various stages of clinical trials and proved to have some efficacy [18–26] . In each design, hepatocytes are inoculated into extracapillary space, either alone or attached to microcarriers, oxygenized plasma flows through the fiber lumina. Since the oxygen-binding ability of plasma is less than one-tenth that of whole blood, the oxygen supply to hepatocytes in these systems is far short of demand [27–29] . This problem leads to poor hepatocyte activity and insufficient hepatic function, thereby decreasing the efficiency of these devices [30] . To address the issue of adequate oxygenation of hepatocytes, we developed a novel BAL system which is based on a direct hemoperfusion typed nonwoven fabric (NWF) bioreactor containing porcine hepatocytes. In this study, we evaluated the efficacy of our BAL system using a D -galactosamine induced FHF in pigs. 2 Materials and methods The study protocol was approved by the Research, Animal Sources, and Animal Care committee, Zhejiang University and met institutional and national guidelines. 2.1 Animals Adult male Chinese experimental miniature pigs (5–10 kg) were purchased from Beijing Agriculture University. Adult male Buloc breeding pigs (20–25 kg) were purchased from Academy of Agriculture Science of Zhejiang Province. All pigs were housed in singular standard cages in an air-conditioned room (21–25 °C), with a 12 h light/dark cycle. Standard laboratory chow and water were given ad libitum. 2.2 Isolation of porcine hepatocytes Hepatocytes were isolated from Chinese experimental miniature pigs using a modified four-step collagenase perfusion method as described elsewhere [31] . Firstly, excised liver lobes were perfused at 37 °C with 300 ml and then at 39 °C with 500 ml of perfusion buffer solution (PBS) composed of 9 g/L NaCl, 0.42 g/L KCl, 2.1 g/L NaHCO 3 , 0.9 g/L glucose and 4.78 g/L Hepes (Sigma-Aldrich Inc., USA) containing 0.37 g/L of EDTA (Gibco, USA). Secondly, the liver lobes were perfused at 39 °C with 500 ml of PBS and 500 ml of PBS containing 8.4 g/L of dispase (Roche Ltd., Switzerland). Thirdly, the liver lobes were perfused with 500 ml of PBS containing 0.5 g/L of collagenase II (Invitrogen Corp., USA) and 0.275 g/L of CaCl 2 ·2H 2 O. The capsula of the liver lobes was then opened and digested parenchyma was collected on ice after filtration through 80-mesh of filter. Finally, the cells were washed three times with ice-cold washing buffer solution (WBS) composed of 7.0 g/L NaCl, 0.461 g/L KCl, 0.13 g/L CaCl 2 ·2H 2 O, 2.38 g/L Hepes and 1.0 g/L BSA (Gibco, USA) through centrifugation at 4 °C and 50× g for 2 min, followed by washing two times with WBS containing 1 g/L of DNase (Gibco, USA) through centrifugation at 4 °C and 50× g for 75 s. The cells were resuspended in DMEM culture media (Gibco, USA) and stored in ice-cool space. The yield varied from 1.2 to 1.5×10 7 hepatocytes per gram of wet liver weight, with viability ranging from 90 to 99%, as determined by trypan blue exclusion test. 2.3 Induction of FHF FHF was induced in Buloc breeding pigs with intravenous administration of D -galactosamine (Sigma-Aldrich Inc., USA) as described elsewhere [32] . Briefly, after a 6 h fasting, anesthesia was achieved with intramuscular administration of Ketamine (4 mg/kg), muscle relaxation was obtained with intravenous administration of Vecuronium Bromide (2 mg/kg). With sterile techniques, two 16-gauge catheters were placed in the right carotid artery and jugular vein, respectively. Animals were then allowed to wake up and to move freely in cages. Twenty-four hours after the cannulation, D -galactosamine was administrated intravenously to unanesthetized pigs at a dose of 1.3 g/kg body weight. Before injection, D -galactosamine was dissolved in 150 ml of 5% dextrose in water and adjusted to pH 6.8 with 1 N NaOH, then used within 2 h. 2.4 BAL system The BAL system consisted of a roller pump, a heparin pump, and an NWF-bioreactor (obtained from Kuraray Medical, Japan) which was placed in an incubator keeping an internal temperature of 37 °C ( Fig. 1 ). The volume of the entire system was approximately 120 ml. The NWF-bioreactor was designed with 500 polysulfone-based hollow fibers, which were spirally wound with nonwoven fabric polytetrafluoroethylene ( Fig. 2 ). The three-dimensional nonwoven fabric provides matrix which allows for hepatocytes immobilization and aggregation at high density (5×10 7 cells/ml). The semipermeable membrane of hollow fibers serves as exchangers and immuno-protective barriers, whole blood flows through the intra-luminal space of hollow fibers into direct contact with hepatocytes for effective oxygen supply, CO 2 removal and material exchange, thereby reducing the diffusion distance and allowing mass exchange similar to the situation in the sinusoids of the liver parenchyma. 2.5 Groups Fifteen FHF pigs were divided into: a BAL group ( n =5), in which pigs received the BAL treatment with hepatocytes, a sham BAL group (device control, n =5), in which pigs received the BAL treatment without hepatocytes, and a FHF group (control, n =5), in which pigs only received intensive care for establishing the basic parameters of the FHF model. 2.6 BAL procedure BAL treatment initiated at 12 h post D -galactosamine administration. Continued anesthesia was achieved by intravenous administration of Diprivan (AstraZeneca, Italy) at a dose of 10 mg/kg h. Pigs in the BAL and the sham BAL group were connected to the BAL device. Twenty milliliters of DMEM medium containing 1.0–1.3×10 9 porcine hepatocytes was inoculated into the NWF-bioreactor, and whole blood perfused through the intra-luminal space at a rate of 40 mL/min for a duration of 6 h. Heparin (100 U/kg) was administered intravenously at the start of treatment and continued at a dose of 40 U/kg h into the circuit, and removed 30 min before the end of the treatment. 2.7 Parameters Blood samples were collected for measurement of hemoglobin, platelet, prothrombin time (PT), ammonia, amino acid, creatinine, blood urea nitrogen, total bilirubin, bile acid, aspartate aminotransferase (AST), glucose and lactate, etc. Animal survival was measured up to 168 h to compare survival between three groups. 2.8 Statistics Values are presented as mean±SD. Statistical analysis was performed using a one-way ANOVA and t -test. Survival time was analyzed using the Kaplan–Meier method, and significance was tested with the log-rank test. A two-tailed P value <0.05 was considered significant. All data were analyzed with SPSS software (11.0). 3 Results 3.1 Clinical course and neurological status All pigs tolerated the BAL treatment well. No obvious coagulation was observed in the treatment period. After the BAL treatment, pigs awoke, stood, ate and drank freely. All pigs except two in the BAL group subsequently developed grade IV hepatic encephalopathy. The onset of hepatic encephalopathy was significantly delayed in the BAL group (61±8 h) as compared with both control groups (FHF group: 44±6 h; sham BAL group: 40±8 h, P <0.05). 3.2 Survival All pigs died, except two in the BAL group, and these were sacrificed 90 days later. Survival time ( Fig. 3 ) was significantly prolonged in the BAL group (106±23 h) as compared with both control groups (FHF group: 48±7 h; sham BAL group: 43±8 h, P <0.05). Survival time between both control groups was not significantly different ( P >0.05). 3.3 Biochemistry parameters As Fig. 4 shows, all pigs showed marked increases in PT, plasma ammonia and lactate acid levels, and a significant decrease in plasma glucose levels 12 h post D -galactosamine administration. In the BAL group, the plasma ammonia levels significantly decreased from 163.00±15.65 to 139.80±13.97 μmol/L during the BAL treatment ( P =0.01). Contrarily, the plasma ammonia levels in the FHF and the sham BAL groups significantly increased and reached 198.80±21.44 and 189.40±23.03 μmol/L, respectively. No significant difference in plasma ammonia levels between both control groups was observed ( P >0.05). The plasma glucose levels in all groups decreased during the treatment, since no supply of glucose in the study. However, significantly higher levels of glucose were seen in the BAL group as compared with both control groups at the end of the BAL treatment ( P <0.05). The serum lactate levels in the BAL group decreased markedly from 6.22±1.28 to 2.80±0.72 mmol/L, the post-BAL serum lactate levels in the BAL group was lower than that in both control groups ( P <0.01). PT in all groups was prolonged in the BAL treatment period. However, it was shorter in the BAL group (20.52±2.96 s) than that in the sham BAL group (25.14±2.93 s) at the end of BAL treatment ( P <0.05). Table 1 lists other parameters related to liver and kidney functions. The levels of AST, total bilirubin, bile acid gradually increased during the BAL treatment, showing no statistical differences between three groups. However, Fischer index significantly increased in the BAL group as compared with both control groups ( P <0.05). 3.4 Hepatocytes viability When the BAL treatment terminated, the NWF-bioreactors were perfused with 0.25% trypsinase, and hepatocytes were collected through centrifugation after washing with PBS three times. The hepatocytes viability varied between 75 and 79%, as determined by trypan blue exclusion test. 4 Discussion BAL is anticipated to be an effective treatment of choice for patients with FHF. For achieving better efficacy, most efforts have been contributed to the configurations of bioreactors for the purpose of in vitro mimicking the three dimensional microstructure of liver sinusoid, thereby maintaining viable functional hepatocytes outside of the body. Studies demonstrated that BAL systems based on hollow fiber bioreactors, for example, the HepatAssist system [28] and the Extracorporeal Liver Assist Device (ELAD) [27] , suffer from oxygen substrate limitations. In these systems, a large proportion of hepatocytes may be anoxic and lose their functions under typical operating conditions. Gerlach et al. [33] reported use of their own system which utilized a more sophisticated bioreactor, and demonstrated its efficacy in anhepatic pigs. This bioreactor consists of three bundles of interwoven capillaries that create a three-dimensional extracapillary space which provides an optimized compartment for hepatocytes attachment and reorganized into aggregates. However, the Gerlach bioreactor is too complex to run [17] . Another promising bioreactor design with an integral oxygenator was developed by Chamuleau and his colleagues [34] . Their bioreactor uses a spirally wound nonwoven polyester matrix which provides a three-dimensional structure for hepatocyte attachment, and integrated hollow-fiber membranes for oxygen supply. This design creates an environment that is more amenable to the optimal maintenance of hepatocytes, enabling them to retain their functions. The major disadvantage of the Chamuleau system is the direct contact between plasma and porcine liver cells. Consequently, there is no barrier for porcine pathogens. Moreover, no evidence demonstrated the efficacy of the internal oxygenator through direct comparison to similar bioreactor designs without an internal membrane oxygenator. Our BAL system is based on a direct hemoperfusion typed NWF-bioreactor. The bioreactor incorporates a spirally wound polyester matrix sheet that includes an integral hollow-fiber compartment for whole blood perfusion. At a certain extent, the configuration of our bioreactor is similar to the Chamuleau bioreactor. However, our bioreactor has no oxygenation capillaries, therefore, adequate oxygenation via whole blood instead of oxygenized plasma maybe sufficient to the hepatocytes during the in vivo application. Moreover, most of the hepatocytes attached to the surface of nonwoven fabric, only one membrane between the hepatocytes and the blood permits efficient material exchange. For a preclinical trial, a large clinically relevant animal model of FHF with high mortality as well as the potential for recovery is required [35] . Animal model of FHF induced by surgical methods, including hepatectomy and ischemic models, seems not suitable for testing the efficacy of a BAL device because they lack potential reversibility. Studies demonstrated that D -galactosamine induced FHF model possessed high reproducibility and potential reversibility, which met the majority of the criteria set by Terblanche and Hickman [32,36] . Moreover, this kind of animal model is morphologically similar to virus- or drug-related hepatic failure in human beings, as it is associated with neurological deterioration, hypoglycemia and death from liver failure [37–39] . In this study, we first established an FHF model in pigs by the administration of a rather high dose of D -galactosamine. The progression of FHF in pigs is reflected principally as rapid increases in plasma ammonia, serum bilirubin, AST, lactate acid levels, marked decreases in plasma glucose levels and Fischer index as well as significant prolongation in PT. These disturbances demonstrated that the cause of death in pigs was due to FHF. An effective BAL system should be capable of temporarily providing the deintoxication and synthesis functions of liver. In this study, pigs in both control groups appeared with dramatically decreased glucose levels, since no special efforts to normalize glucose concentration were performed during the BAL treatment. Contrarily, 6 h BAL treatment could maintain the plasma glucose concentration. In addition, a rapid decrease in serum lactate acid levels could be seen at the end of the BAL treatment. Normalized plasma glucose levels and decreased serum lactate levels indicated that hepatocytes in the NWF-bioreactors had exerted beneficial metabolic effects on the FHF pigs. Accumulation of plasma ammonia and aromatic amino acid is associated with the development of encephalopathy in FHF [40] . In addition, studies in vivo demonstrate that ammonia exerts an inhibitive effect on liver regeneration in animal models [41,42] . Thus the levels of ammonia and Fischer index are always used to evaluate the BAL system's effects in animal and clinical tests. In this study, the BAL group showed marked beneficial effects on ammonia levels compared with both control groups. Decreased ammonia levels during the BAL treatment indicated that our BAL system carried out positive ammonia removal function. Furthermore, the difference in Fischer index was found to be significant in the BAL group than that in both control groups. This indicated that 6 h BAL treatment also has a high compensatory capacity for regulating and maintaining the serum amino acid balance of FHF pigs. Progressing hepatic failure is also associated with coagulopathy, which manifests as a prolongation of PT and decrease in platelet count. In this study, no significant reduction of the PT in the BAL group was observed, this maybe duo to the administration of heparin during the BAL treatment. However, PT in the BAL group was shorter than that in the sham BAL group. This indicated that porcine hepatocytes in the NWF-bioreactor did synthesize some of the vitamin K-dependent clotting factors, which is consistent with studies by Patzer et al. [43] . However, the decreased platelet was not improved by the BAL treatment. Animal survival is usually considered as a definitive index for accessing the effects of a BAL system [44–47] . In a controlled study, dogs with ischemic liver failure treated with the HepatAssist incorporated with 5×10 9 matrix-attached hepatocytes showed significant neurological and biochemical improvements, but life was not prolonged [48,49] . However, treatment of ischemic pigs with the Chamuleau system which housing 1.4×10 10 porcine hepatocytes significantly increased survival time in association with a significant decrease in blood ammonia [50] . In this study, 6 h BAL treatment significantly prolonged animal survival time. This indicated that porcine hepatocytes in the NWF-bioreactor had exerted beneficial effects on animal survival. A recent study indicated that at lest 10 10 viable hepatocytes in a BAL bioreactor would be needed to support a patient's failing liver [51] . In this study, 10 9 hepatocytes were seeded at high density in a NWF bioreactor, although the population of hepatocytes was far from those in the Chamuleau system [50] and HepatAssist system [49] , our data suggested that the performance of our system maybe equal to the Chamuleau system, and probably superior to that of the HepatAssist system. Moreover, our bioreactor is easier to scale up by increasing the quantity of hollow fibers and the circles of wound nonwoven fabric, without losing the advantage of adequate oxygen supply, because each hollow fiber shared in theory the same portion of whole blood from the inlet of the cartridge. Although it is well known that hepatocytes dedifferentiate in vitro, the study demonstrated that uncultured porcine hepatocytes fully attached to the bioreactor within 2 h and were metabolically functional within 4 h [52] . Additionally, freshly isolated porcine hepatocytes loading inside the bioreactor allowed for the maintaining of liver cell differentiated functions [52] . Our results demonstrated that hepatocyes in the NWF-bioreactor still keep a high viability rate at the end of the treatment, possibly due to the bioreactor being perfused with whole blood instead of plasma. This suggested that the duration of the BAL treatment period could be further prolonged. Regarding the origin of hepatocytes, human hepatocytes are obviously the optimal choice for the BAL system. However, the limited availability of donor liver makes their use less feasible. Porcine hepatocytes are considered to be the best alternative to human hepatocytes for BAL because of anatomical and physiological similarities to human hepatocytes [48] . The major concern in the use of porcine hepatocytes is the risk of transfection of porcine endogenous retroviruses to the human population and severe immunological complications [53,54] , despite that no direct evidence of such a transfection has been observed in in vivo studies [55,56] . The gradual rise of serum aminotransferases, total bilirubin, and bile acid in the FHF pigs indicated that the 6 h BAL treatment may be insufficient to eliminate these accumulated materials. From the changes in hemoglobin value, leukocytes and platelet number, no severe damages were observed to exert on pig blood by the direct hemoperfusion through the BAL system. 5 Conclusion We therefore conclude that the BAL based on a direct hemoperfusion typed NWF-bioreactor with porcine hepatocytes appears to be effective in the treatment of FHF in pigs, with a prolonged survival time. The safety and efficacy of this novel system seems to be promising for human clinical care. Acknowledgements We wish to thank Dr. N. Tanaka and Dr. N. Kobayashi (Department of Gastroenterological Surgery, Transplantation and Surgical Oncology, Okayama University, Okayama, Japan) for their technical help. The work presented in this paper was supported by the National Hi-tech R&D Program of China (No. 2003AA205150) and the Key Technologies R&D Program of China (No. 2004BA706B02-01). References [1] A.O. Shakil D. Kramer G.V. Mazariegos J.J. Fung J. Rakela Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria Liver Transpl 6 2000 163 169 [2] A. Mas J. Rodes Fulminant hepatic failure Lancet 349 1997 1081 1085 [3] R.W. Chapman D. Forman R. Peto R. Smallwood Liver transplantation for acute hepatic failure? Lancet 335 1990 32 35 [4] G. Ostapowicz W.M. Lee Acute hepatic failure: a Western perspective J Gastroenterol Hepatol 15 2000 480 488 [5] B. van Hoek J. de Boer K. Boudjema R. Williams O. Corsmit O.T. Terpstra Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry J Hepatol 30 1999 699 705 [6] S. Miwa Y. Hashikura A. Mita T. Kubota H. Chisuwa Y. Nakazawa Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure Hepatology 30 1999 1521 1526 [7] J.A. Goss C.R. Shackleton M. Maggard K. Swenson P. Seu S.V. McDiarmid Liver transplantation for fulminant hepatic failure in the pediatric patient Arch Surg 133 1998 839 846 [8] C.O. Esquivel E.B. Keeffe G. Garcia J.C. Imperial M.T. Millan H. Monge Resection versus transplantation for hepatocellular carcinoma J Gastroenterol Hepatol 14 1999 S37 S41 [9] A.L. Friedman Why bioartificial liver support remains the Holy Grail ASAIO J 44 1998 241 243 [10] P. Caraceni D.H. Van Thiel Acute liver failure Lancet 345 1995 163 169 [11] S.D. Lidofsky Liver transplantation for fulminant hepatic failure Gastroenterol Clin North Am 22 1993 257 269 [12] R.D. Hughes R. Williams Use of bioartificial and artificial liver support devices Semin Liver Dis 16 1996 435 444 [13] V. Dixit G. Gitnick The bioartificial liver: state-of-the-art Eur J Surg Suppl 1998 71 76 [14] S. Nagamori S. Hasumura T. Matsuura H. Aizaki M. Kawada Developments in bioartificial liver research: concepts, performance, and applications J Gastroenterol 35 2000 493 503 [15] B. Busse J.C. Gerlach Bioreactors for hybrid liver support: historical aspects and novel designs Ann N Y Acad Sci 875 1999 326 339 [16] J.W. Allen T. Hassanein S.N. Bhatia Advances in bioartificial liver devices Hepatology 34 2001 447 455 [17] A.J. Strain J.M. Neuberger A bioartificial liver—state of the art Science 295 2002 1005 1009 [18] N.L. Sussman G.T. Gislason C.A. Conlin J.H. Kelly The Hepatix extracorporeal liver assist device: initial clinical experience Artif Organs 18 1994 390 396 [19] A.A. Demetriou R.S. Brown Jr. R.W. Busuttil J. Fair B.M. McGuire P. Rosenthal Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure Ann Surg 239 2004 660 667 [discussion 667–670] [20] A.J. Ellis R.D. Hughes J.A. Wendon J. Dunne P.G. Langley J.H. Kelly Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure Hepatology 24 1996 1446 1451 [21] F.D. Watanabe C.J. Mullon W.R. Hewitt N. Arkadopoulos E. Kahaku S. Eguchi Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial Ann Surg 225 1997 484 491 discussion 491–484 [22] G.V. Mazariegos D.J. Kramer R.C. Lopez A.O. Shakil A.J. Rosenbloom M. DeVera Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients Asaio J 47 2001 471 475 [23] E. Morsiani P. Pazzi A.C. Puviani M. Brogli L. Valieri P. Gorini Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients Int J Artif Organs 25 2002 192 202 [24] A. Mundt G. Puhl A. Muller I. Sauer C. Muller R. Richard A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support Int J Artif Organs 25 2002 542 548 [25] A. Donini U. Baccarani A. Risaliti A. Degrassi F. Bresadola Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device Am J Gastroenterol 95 2000 1102 1104 [26] M.P. van de Kerkhove E. Di Florio V. Scuderi A. Mancini A. Belli A. Bracco Phase I clinical trial with the AMC-bioartificial liver Int J Artif Organs 25 2002 950 959 [27] P.D. Hay A.R. Veitch M.D. Smith R.B. Cousins J.D. Gaylor Oxygen transfer in a diffusion-limited hollow fiber bioartificial liver Artif Organs 24 2000 278 288 [28] P.D. Hay A.R. Veitch J.D. Gaylor Oxygen transfer in a convection-enhanced hollow fiber bioartificial liver Artif Organs 25 2001 119 130 [29] J.F. Patzer II Oxygen consumption in a hollow fiber bioartificial liver—revisited Artif Organs 28 2004 83 98 [30] M. Shito A.W. Tilles R.G. Tompkins M.L. Yarmush M. Toner Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure J Surg Res 111 2003 53 62 [31] M. Maruyama T. Totsugawa T. Kunieda T. Okitsu N. Shibata M. Takesue Hepatocyte isolation and transplantation in the pig Cell Transplant 12 2003 593 598 [32] K. Kalpana H.S. Ong K.C. Soo S.Y. Tan J. Prema Raj An improved model of galactosamine-induced fulminant hepatic failure in the pig J Surg Res 82 1999 121 130 [33] J.C. Gerlach Long-term liver cell cultures in bioreactors and possible application for liver support Cell Biol Toxicol 13 1997 349 355 [34] L.M. Flendrig J.W. la Soe G.G. Jorning A. Steenbeek O.T. Karlsen W.M. Bovee In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates J Hepatol 26 1997 1379 1392 [35] M.P. van de Kerkhove R. Hoekstra T.M. van Gulik R.A. Chamuleau Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research Biomaterials 25 2004 1613 1625 [36] J. Terblanche R. Hickman Animal models of fulminant hepatic failure Dig Dis Sci 36 1991 770 774 [37] D. Keppler R. Lesch W. Reutter K. Decker Experimental hepatitis induced by D-galactosamine Exp Mol Pathol 9 1968 279 290 [38] A. Medline F. Schaffner H. Popper Ultrastructural features in galactosamine-induced hepatitis Exp Mol Pathol 12 1970 201 211 [39] A.M. Jonker F.W. Dijkhuis F.G. Kroese M.J. Hardonk J. Grond Immunopathology of acute galactosamine hepatitis in rats Hepatology 11 1990 622 627 [40] R. Williams A.E. Gimson Intensive liver care and management of acute hepatic failure Dig Dis Sci 36 1991 820 826 [41] W.R. Ellis P.K. Chu I.M. Murray-Lyon The influence of ammonia and octanoic acid on liver regeneration in the rat Clin Sci (London) 56 1979 95 97 [42] L. Zieve M. Shekleton C. Lyftogt K. Draves Ammonia, octanoate and a mercaptan depress regeneration of normal rat liver after partial hepatectomy Hepatology 5 1985 28 31 [43] J.F. Patzer II G.V. Mazariegos R. Lopez Preclinical evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System J Am Coll Surg 195 2002 299 310 [44] L.M. Flendrig R.A. Chamuleau M.A. Maas J. Daalhuisen B. Hasset C.G. Kilty Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability J Hepatol 30 1999 311 320 [45] T.D. Sielaff M.Y. Hu B. Amiot M.D. Rollins S. Rao B. McGuire Gel-entrapment bioartificial liver therapy in galactosamine hepatitis J Surg Res 59 1995 179 184 [46] V. Cuervas-Mons A. Colas J.A. Rivera E. Prados In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs Transplantation 69 2000 337 344 [47] J. Uchino T. Tsuburaya F. Kumagai T. Hase T. Hamada T. Komai A hybrid bioartificial liver composed of multiplated hepatocyte monolayers ASAIO Trans 34 1988 972 977 [48] J. Rozga F. Williams M.S. Ro D.F. Neuzil T.D. Giorgio G. Backfisch Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells Hepatology 17 1993 258 265 [49] J. Rozga M.D. Holzman M.S. Ro D.W. Griffin D.F. Neuzil T. Giorgio Development of a hybrid bioartificial liver Ann Surg 217 1993 502 509 discussion 509–511 [50] L.M. Flendrig F. Calise E. Di Florio A. Mancini A. Ceriello W. Santaniello Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver Int J Artif Organs 22 1999 701 709 [51] J. Tsiaoussis P.N. Newsome L.J. Nelson P.C. Hayes J.N. Plevris Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl 7 2001 2 10 [52] D.C. Mears G. Stewart J. Sun K. Woodman R. Bourne L. Wang Experience with a porcine hepatocyte-based bioartificial liver support system Transplant Proc 35 2003 441 442 [53] U. Martin M.E. Winkler M. Id H. Radeke L. Arseniev Y. Takeuchi Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV) Xenotransplantation 7 2000 138 142 [54] C. Patience Y. Takeuchi R.A. Weiss Infection of human cells by an endogenous retrovirus of pigs Nat Med 3 1997 282 286 [55] R. Kuddus J.F. Patzer R. Lopez G.V. Mazariegos B. Meighen D.J. Kramer Valuation of transmission of porcine endogenous retrovirus into patients subjected to hemoperfusion using an extracorporeal bioartificial liver support system Transplant Proc 33 2001 1976 [56] E. Falasca V. Adami G. Astori A. Donini F. Biffoni A. Degrassi Porcine endogenous retrovirus does not infect human cells using a bioartificial liver model system Transplant Proc 33 2001 1780 1781
What problem does this paper attempt to address?
-
Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study
Pengcheng Zhou,Li Shao,Lifu Zhao,Guoliang Lv,Xiaoping Pan,Anye Zhang,Jianzhou Li,Ning Zhou,Deying Chen,Lanjuan Li
DOI: https://doi.org/10.1038/srep26070
IF: 4.6
2016-01-01
Scientific Reports
Abstract:Bioartificial livers may act as a promising therapy for fulminant hepatic failure (FHF) with better accessibility and less injury compared to orthotopic liver transplantation. This study aims to evaluate the efficacy and safety of a fluidized bed bioartificial liver (FBBAL) and to explore its therapeutic mechanisms based on metabolomics. FHF was induced by D-galactosamine. Eighteen hours later, pigs were treated with an FBBAL containing encapsulated primary porcine hepatocytes (B group), with a sham FBBAL (containing cell-free capsules, S group) or with only intensive care (C group) for 6 h. Serum samples were assayed using ultra-performance liquid chromatography-mass spectrometry. The difference in survival time (51.6 ± 7.9 h vs. 49.3 ± 6.6 h) and serum metabolome was negligible between the S and C groups, whereas FBBAL treatment significantly prolonged survival time (70.4 ± 11.5h, P < 0.01) and perturbed the serum metabolome, resulting in a marked decrease in phosphatidylcholines, lysophosphatidylcholines, sphingomyelinase, and fatty acids and an increase in conjugated bile acids. The FBBAL exhibits some liver functions and may exert its therapeutic effect by altering the serum metabolome of FHF pigs. Moreover, alginate–chitosan capsules have less influence on serum metabolites. Nevertheless, the alterations were not universally beneficial, revealing that much should be done to improve the FBBAL.
-
Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs.
Guoliang Lv,Lifu Zhao,Anye Zhang,Weibo Du,Yu Chen,Chengbo Yu,Xiaoping Pan,Yimin Zhang,Tao Song,Jiansheng Xu,Yu Chen,Lanjuan Li
DOI: https://doi.org/10.1002/bit.23150
IF: 3.8
2011-01-01
Biotechnology and Bioengineering
Abstract:Bioartificial liver (BAL) support system has been proposed as potential treatment method for end-stage liver diseases. We described an improved BAL system based on a choanoid fluidized bed bioreactor containing alginate-chitosan encapsulated primary porcine hepatocytes. The feasibility, safety, and efficiency of this device were estimated using an allogeneic fulminant hepatic failure (FHF) model. FHF was induced with intravenous administration of D-galactosamine. Thirty FHF pigs were divided into three groups: (1) an FHF group which was only given intensive care; (2) a sham BAL group which was treated with the BAL system with empty encapsulation, and (3) a BAL group which was treated with the BAL system containing encapsulated freshly isolated primary porcine hepatocytes. The survival times and biochemical parameters of these animals were measured, and properties of the encapsulations and hepatocytes before and after perfusion were also evaluated. Compared to the two control groups, the BAL-treated group had prolonged the survival time and decreased the blood lactate levels, blood glucose, and amino acids remained stable. No obvious ruptured beads or statistical decline in viability or function of encapsulated hepatocytes were observed. This new fluidized bed BAL system is safe and efficient. It may represent a feasible alternative in the treatment of liver failure. Biotechnol. Bioeng. 2011; 108: 2229-2236. (C) 2011 Wiley Periodicals, Inc.
-
Effects of a Non-Woven Fabric Bioreactor Based Bioartificial Liver on Fulminant Hepatic Failure in Pigs
杜维波,李兰娟,章益民,李君,陈佳佳,潘小平,曹红翠,陈瑜,陈月美,俞海英,盛国平
DOI: https://doi.org/10.3760/j.issn:1000-6680.2006.01.009
2006-01-01
Abstract:Objective In this paper, the design of a bioartificial liver (BAL) based on non-woven fiber bioreactor is described and evaluated using a pig fulminant liver failure model. Methods Fulminant liver failure (FHF) was induced with D-galactosamine hydrochloride in a dose of 1.3 g/kg body weight in each pig. 12 hours later, the pigs were divided into three groups: (1) a BAL group (n=5), in which pigs received BAL treatment with 1.0 to 1.3—109 hepatocytes for a duration of 6 hours, (2) a sham BAL group (n=5), in which pigs received BAL treatment without hepatocytes, and (3) a FHF group (n=5), in which pigs only received intensive care. Parameters related to liver function and animal survivals up to 168 h were determined. Results In the BAL group, blood ammonia and serum L-lactate levels were lower, and serum glucose levels and Fischer index were higher than those in the other two groups. The survival time of FHF pigs in the BAL group was significantly prolonged (106±23 h) compared with the sham BAL (43±8 h) and the FHF group (48±7 h). Conclusions The non-woven fabric bioreactor based BAL system appears to be effective in treatment of FHF in pigs.
-
Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs
Jun Weng,Xu Han,Fanhong Zeng,Yue Zhang,Lei Feng,Lei Cai,Kangyan Liang,Shusong Liu,Shao Li,Gongbo Fu,Min Zeng,Yi Gao
DOI: https://doi.org/10.7150/thno.58515
IF: 11.6
2021-01-01
Theranostics
Abstract:Rationale: Acute liver failure (ALF) causes severe liver injury and a systemic inflammatory response, leading to multiorgan failure with a high short-term mortality. Bioartificial liver (BAL) therapy is a promising approach that is hampered by the lack of appropriate bioreactors and carriers to retain hepatic cell function and poor understanding of BAL treatment mechanisms in ALF and extrahepatic organ injury. Recently, we used a fiber scaffold bioreactor (FSB) for the high-density, three-dimensional (3D) culture of primary porcine hepatocytes (PPHs) combined with an absorption component to construct a BAL and verified its function in a D-galactosamine (D-gal)-induced ALF porcine model to evaluate its protective effects on the liver and extrahepatic organs. Methods: Male pigs were randomized into standard/supportive therapy (ST), ST+no-cell BAL (ST+Sham BAL) and ST+BAL groups and received treatment 48 h after receiving a D-gal injection. Changes in blood chemistry and clinical symptoms were monitored for 120 h. Tissues and plasma were collected for analysis by pathological examination, immunoblotting, quantitative PCR and immunoassays. Results: PPHs cultured in the FSB obtained sufficient aeration and nutrition for high-density, 3D culture and maintained superior viability and functionality (biosynthesis and detoxification) compared with those cultured in flasks. All the animals developed ALF, acute kidney injury (AKI) and hepatic encephalopathy (HE) 48 h after D-gal infusion and received corresponding therapies. Animals in the BAL group showed markedly improved survival (4/5; 80%) compared with those in the ST+Sham BAL (0/5; p < 0.001) and ST (0/5; p < 0.001) groups. The levels of blood ammonia and biochemical and inflammatory indices were alleviated after BAL treatment. Increased liver regeneration and attenuations in the occurrence and severity of ALF, AKI and HE were observed in the ST+BAL group compared with the ST (p = 0.0009; p = 0.038) and ST+Sham BAL (p = 0.011; p = 0.031) groups. Gut leakage, the plasma endotoxin level, bacterial translocation, and peripheral and neuroinflammation were alleviated in the ST+BAL group compared with those in the other groups. Conclusions: BAL treatment enhanced liver regeneration and alleviated the systemic inflammatory response and extrahepatic organ injury to prolong survival in the ALF model and has potential as a therapeutic approach for ALF patients.
medicine, research & experimental
-
Efficacy of Coupled Low-Volume Plasma Exchange with Plasma Filtration Adsorption in Treating Pigs with Acute Liver Failure: A Randomised Study.
Ning Zhou,Jianzhou Li,Yimin Zhang,Juan Lu,Ermei Chen,Weibo Du,Jie Wang,Xiaoping Pan,Danhua Zhu,Ying Yang,Yu Chen,Hongcui Cao,Lanjuan Li
DOI: https://doi.org/10.1016/j.jhep.2015.03.018
IF: 25.7
2015-01-01
Journal of Hepatology
Abstract:Background & Aims: Extracorporeal blood purification systems for supportive therapy of liver failure are widely used. We developed a novel blood purification system, named Li's artificial liver system (Li-ALS), which couples low-volume plasma exchange (low-volume PE) with plasma filtration adsorption (PFA). This study aims to evaluate the efficacy of our novel system in pigs with acute liver failure (ALF).Methods: Thirty-two pigs were infused with D-galactosamine (1.3 g/kg) to induce ALF. All animals were equally and randomly divided into four groups: the ALF control group received intensive care, the PFA group underwent five hour plasma recycling filtration and adsorption purification, the low-volume PE group received one hour low-volume PE, and the Li-ALS group underwent one hour low-volume PE, followed by five hour PFA. Intervention was initiated 36 hours after drug administration. The efficacy of each treatment was assessed by survival time and improvement in hematological, biochemical, and immunohistological parameters.Results: Pigs in the Li-ALS group survived longer than those in the other groups (p < 0.001, ALF control: 60 +/- 2 h; PFA group: 74 +/- 2 h; low-volume PE group: 75 +/- 2 h; and Li-ALS group: 90 +/- 3 h). Liver enzyme, bilirubin, bile acid and blood ammonia levels were decreased significantly after Li-ALS treatment, and increases in inflammatory cytokines were ameliorated. A higher hepatocyte regeneration index was also observed in the Li-ALS group.Conclusion: Our novel Li-ALS could expedite liver regeneration and improve survival time; hence, it could be promising for treating ALF. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.
-
Observations on Hemodynamic Changes and Graft Function in Pig Model for Auxiliary Partial Orthotopic Liver Transplantation
史留斌,彭承宏,彭淑牖,何伟,刘颖斌,王涌,唐结
DOI: https://doi.org/10.3969/j.issn.1007-9610.2003.06.013
2003-01-01
Abstract:Objective: To observe the intraoperative hemodynamic changes and graft function in a new pig model of auxiliary partial orthotopic liver transplantation. Methods: Sixteen healthy male or female domestic pigs, weighing 22 to 27 kg, were randomly selected to be either a donor (n=8) or a recipient(n=8). After intubation, anesthesia was maintained by pentothal sodium. The left lobe of the donor liver was resected in vitro, the right lobe was used as a graft. Donor suprahepatic inferior vena cava was anastomosed end-to-side to host suprahepatic inferior vena cava, donor portal vein end-to-side to host portal vein, donor hepatic artery end-to-end to host spleen artery. The common bile duct of the donor was intubated and bile was collected with an extracorporeal bag. At the end of operation, the donor's infrahepatic inferior vena cava was ligated. Cold ischemia time averaged about (58±4.0) min. Immunosuppressants were not administered and antibiotics were administered for three days after operation. During transplantation, arterial blood pressure, central venous pressure were monitored. BB, SB and pH of arterial blood samples were determined and analysed in order to assess the impact of operation on the animals. Color ultrasound examinations were performed 5 days after operation in some recipients and autopsy was made on all the recipients. Wedge biopsy specimens of every pig was obtained and stained with hematoxylin-eosin. Results: Seven of the 8 recipients (87.5%) survived for five days, one recipient did not recover from anesthesia, probably due to hyperkalemia and severe acidosis. The hemodynamis recovered rapidly and stabilized after graft reperfusion. Color ultrasound examination showed an increase of blood flow of graft on the 5th day compared to the 1st day after operation. When the animals were sacrificed on the 5th day after operation, thrombosis of HV and PV were not found; histopathological examination of liver specimens revealed evidence of damage with mild steatosis and sporadic necrotic foci and focal hepatic lobules degeneration in the graft,especially around the pericentral venous area. Infiltration by inflammatory cells was mild in the portal or central veinous area. Conclusions: The new pig model was successfully tried in our laboratory. The new procedure showed the advantages of easy anastomoses, stable intraoperative hemodynamics, less complications and high survival rate.
-
Establishment and further improvement of D-galactosamine induced acute hepatic failure in Duroc breeding pigs
Wei-bo DU,Xiao-ping PAN,Jia-jia CHEN,Yi-min ZHANG,Yu CHEN,Lan-juan LI
DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2009.04.005
2009-01-01
Abstract:Objective To establish and improve the acute hepatic failure model in pigs induced with D-galactosamine (D-gal),and explore the feasibility of evaluating preclinical artificial liver devices.Methods Nineteen Duroc breeding pigs were divided into 4 groups.Fifteen unanesthetic Duroc breeding pigs out of 19 (5 of each group) received intravenously administration of D-gal at a dose of 1.0,1.25 and 1.5 g/kg body weight,respectively.The remaining 4 pigs which received the same volume of 5% dextrose in water served as controls. Clinical data and survival time of pigs were recorded.Blood samples were collected for dynamic testing of plasma ammonia,prothrombin time,liver and renal functions,blood glucose and L-lactate;liver tissues were sampled for pathological examination.The differences between groups were compared using t test and F test.The survival time of pigs was compared by Kaplan-Meier survival analysis and Log Rank test.Results Twelve hours after administration of D-gal,all pigs presented as acute hepatic failure characterized by progressive increases of levels of plasma ammonia,aspartate aminotransferase (AST),total bilirubin (TBil) and L-lactate,the level of blood glucose marked decreased and prothrombin time prolonged (F= 32.33,F=27.817,F=50.097,F=88.382,F=8.211,F=21.227;all P＜0.01);especially in the pigs which received D-gal at a dose of 1.5 g/kg.Except 2 pigs survived for 168 h,the other 3 pigs which received D-gal at a dose of 1.0 g/kg died within 68-84 h,while all pigs which received D-gal at a dose of 1.25 and 1.5 g/kg died within 33-89 h and 23-47 h,respectively.All pigs presented coma before death and liver histopathological examination indicated massive hepatic necrosis with severe hemorrhage.Conclusions D-gal induced acute hepatic failure model in unanesthetic Duroc breeding pig appears potential reversibility and high reproducibility,which has proper therapeutic window.Thus,this model could be applied to evaluate the therapeutic effects and safety of artificial liver devices.
-
The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model
Shin Enosawa,Tomoyuki Miyashita,Tomohiro Saito,Takeshi Omasa,Toshiharu Matsumura
DOI: https://doi.org/10.3727/000000006783981350
Abstract:We developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activity of porcine hepatocytes, while unmodified HepG2 had no such activity. The established GS-HepG2 cells were grown in a circulatory flow bioreactor to 3.5-4.1 x 10(9) cells. Survival time of the animals treated with GS-HepG2 BAL was significantly prolonged compared to the cell-free control (14.52 +/- 5.24 h vs. 8.53 +/- 2.52 h) and the group treated with the BAL consisting of unmodified wild-type HepG2 (9.58 +/- 4.52 h). Comparison showed the cell-containing BAL groups to have significantly fewer incidences of increased brain pressure. Thus, the GS-HepG2 BAL treatment resulted in a significant improvement of survival time and pathological parameters in pigs with ischemic liver failure.
-
Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes
Xiao-Lei Shi,Yimeng Gao,Yupeng Yan,Hucheng Ma,Lulu Sun,Pengyu Huang,Xuan Ni,Ludi Zhang,Xin Zhao,Haozhen Ren,Dan Hu,Yan Zhou,Feng Tian,Yuan Ji,Xin Cheng,Guoyu Pan,Yi-Tao Ding,Lijian Hui
DOI: https://doi.org/10.1038/cr.2016.6
IF: 44.1
2016-01-15
Cell Research
Abstract:Acute liver failure (ALF) is a life-threatening illness. The extracorporeal cell-based bioartificial liver (BAL) system could bridge liver transplantation and facilitate liver regeneration for ALF patients by providing metabolic detoxification and synthetic functions. Previous BAL systems, based on hepatoma cells and non-human hepatocytes, achieved limited clinical advances, largely due to poor hepatic functions, cumbersome preparation or safety concerns of these cells. We previously generated human functional hepatocytes by lineage conversion (hiHeps). Here, by improving functional maturity of hiHeps and producing hiHeps at clinical scales (3 billion cells), we developed a hiHep-based BAL system (hiHep-BAL). In a porcine ALF model, hiHep-BAL treatment restored liver functions, corrected blood levels of ammonia and bilirubin, and prolonged survival. Importantly, human albumin and α-1-antitrypsin were detectable in hiHep-BAL-treated ALF pigs. Moreover, hiHep-BAL treatment led to attenuated liver damage, resolved inflammation and enhanced liver regeneration. Our findings indicate a promising clinical application of the hiHep-BAL system.
cell biology
-
A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs
Wei-Song Xue,Hao-Jie Zhang,Jing-Jing Ke,Yu Fu,Qing Peng,Li Li,Yi Gao,Ke-Bo Zhong
DOI: https://doi.org/10.1016/j.hbpd.2022.06.012
2022-07-01
Abstract:Background : Preventing heterologous protein influx in patients is important when using xenogeneic bioartificial livers (BALs) to treat liver failure. The development of transgenic porcine livers synthesizing human proteins is a promising approach in this regard. Here, we evaluated the safety and efficacy of a transgenic porcine liver synthesizing human albumin (hALB) and coagulation factor VII (hFVII) within a bioartificial system. Methods : Tibetan miniature pigs were randomly subjected to different interventions after surgery-induced partially ischemic liver failure. Group A ( n = 4) was subjected to basic treatment; group B ( n = 4) was to standard medical treatment and wild-type porcine BAL perfusion, and group C ( n = 2) was to standard medical treatment and transgenic BAL perfusion. Biochemical parameters, coagulation status, survival time, and pathological changes were determined. Expressions of hALB and hFVII were detected using immunohistochemistry and enzyme-linked immunosorbent assays. Results : The survival time in group A was 9.75 ± 1.26 days; this was shorter than that in both perfused groups, in which all animals reached an endpoint of 12 days ( P = 0.006). Ammonia, bilirubin, and lactate levels were significantly decreased, whereas albumin and fibrinogen levels were increased after perfusion (all P < 0.05). hALB and hFVII were detected in transgenic BAL-perfused pig serum and ex vivo in the liver tissues. Conclusions : The humanized transgenic pig livers could synthesize and secrete hALB and hFVII ex vivo in a whole organ-based bioartificial system, while maintaining their metabolism, detoxification, transformation, and excretion functions, which were comparable to those observed in wild-type porcine livers. Therefore, the use of transgenic bioartificial whole livers is expected to become a new approach in treating acute liver failure.
gastroenterology & hepatology
-
An Experimental Study of Combined Nonbioartificial Liver for Pigs with Acute Hepatic Failure
LI Ya-ming,ZHANG Jing,ZHAO Jun,CHEN yu,DUAN Zhong-ping
DOI: https://doi.org/10.3969/j.issn.1005-2194.2006.24.010
2006-01-01
Abstract:Objective:To evaluate the efficacy of combined nonbioartificial liver (plasma exchange plus continuous hemofiltration)for large animal model of fulminant hepatic failure induced by D-galactosamine.Methods:28 pigs were divided into two groups at random:control group(n=13) and treatment group(n=15).All of the animals were inducced fulminant hepatic failure with administration of D-galactosamine firstly.48 hours later the treatment group was treated with PE combined with CHF for 12 hours.Efficacy was assessed by comparing the survival time,improvement in manifestation,biochemical and pathological parameters.Results:The treatment group's mean survival time was 128.7±11.3 hours,which was much longer than in the control group 67.9±9.4 hours(p0.01).There were significant differences for serum bilirubin,aminotransferase,ICP,ammonia,prothrombin time and histological manifestation between the two groups at the same time.Conclusion:Combined nonbioartifical liver (PE plus CHF) was effective for fulminant hepatic failure,and may be as a good bridging measure for liver transplantation and other method.
-
Evaluation of a novel hybrid bioartificial liver based on a multi-layer flat-plate bioreactor.
Xiao-Lei Shi,Yue Zhang,Xue-Hui Chu,Bing Han,Jin-Yang Gu,Jiang-Qiang Xiao,Jia-Jun Tan,Zhong-Ze Gu,Hao-Zhen Ren,Xian-Wen Yuan,Yi-Tao Ding
DOI: https://doi.org/10.3748/wjg.v18.i28.3752
IF: 5.374
2012-01-01
World Journal of Gastroenterology
Abstract:AIM: To evaluate the efficacy and safety of a hybrid bioartificial diver (HBAL) system in the treatment of acute liver failure. METHODS: Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into: the HBAL treatment group (n = 8), in which the canines received a 3-h treatment of HBAL; the bioartificial liver (BAL) treatment group (n = 8), in which the canines received a 3-h treatment of BAL; the non-bioartificial liver (NBAL) treatment group (n = 8), in which the canines received a 3-h treatment of NBAL; the control group (n = 8), in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus (PERV) and reverse transcriptase (RT) activity in the plasma were detected. RESULTS: Biochemical parameters were significantly decreased in all treatment groups. The TBIL level in the HBAL group was lower than that in other groups (2.19 +/- 0.55 mu mol/L vs 24.2 +/- 6.45 mu mol/L, 12.47 +/- 3.62 mu mol/L, 3.77 +/- 1.83 mu mol/L, P < 0.05). The prothrombin time (PT) in the BAL and HBAL groups was significantly shorter than the NBAL and control groups (18.47 +/- 4.41 s, 15.5 +/- 1.56 s vs 28.67 +/- 5.71 s, 21.71 +/- 3.4 s, P < 0.05), and the PT in the HBAL group was shortest of all the groups. The albumin in the BAL and HBAL groups significantly increased and a significantly higher level was observed in the HBAL group compared with the BAL group (27.7 +/- 1.7 g/L vs 25.24 +/- 1.93 g/L). In the HBAL group, the ammonia levels significantly decreased from 54.37 +/- 6.86 to 37.75 +/- 6.09 after treatment (P < 0.05); there were significant difference in ammonia levels between other the groups (P < 0.05). The levels of antibodies were similar before and after treatment. The PERV RNA and the RT activity in the canine plasma were all negative. CONCLUSION: The HBAL showed great efficiency and safety in the treatment of acute liver failure. (C) 2012 Baishideng. All rights reserved.
-
Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure
Harvey S. Chen,Dong Jin Joo,Mohammed Shaheen,Yi Li,Yujia Wang,Jian Yang,Clara T. Nicolas,Kelly Predmore,Bruce Amiot,Gregory Michalak,Taofic Mounajjed,Jeff Fidler,Walter K. Kremers,Scott L. Nyberg
DOI: https://doi.org/10.1002/hep.30184
IF: 17.298
2018-12-27
Hepatology
Abstract:Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio-artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild-type large white swine (20 kg-30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24-48 hours after hepatectomy: Group1-standard medical therapy (SMT, n = 6); Group2-SMT plus bio-artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3-SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200-g group survived to 90 hours (P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200-g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200-g group compared with the SMT (P < 0.01) and 0-g (P < 0.01) groups. Ki-67 staining showed increased positive staining at 48 hours following hepatectomy (P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
gastroenterology & hepatology
-
Advances in cell sources of hepatocytes for bioartificial liver.
Xiao-Ping Pan,Lan-Juan Li
DOI: https://doi.org/10.1016/S1499-3872(12)60230-6
IF: 3.355
2012-01-01
Hepatobiliary & Pancreatic Diseases International
Abstract:Orthotopic liver transplantation (OLT) is the most effective therapy for liver failure. However, OLT is severely limited by the shortage of liver donors. Bioartificial liver (BAL) shows great potential as an alternative therapy for liver failure. In recent years, progress has been made in BAL regarding genetically engineered cell lines, immortalized human hepatocytes, methods for preserving the phenotype of primary human hepatocytes, and other functional hepatocytes derived from stem cells.A systematic search of PubMed and ISI Web of Science was performed to identify relevant studies in English language literature using the key words such as liver failure, bioartificial liver, hepatocyte, stem cells, differentiation, and immortalization. More than 200 articles related to the cell sources of hepatocyte in BAL were systematically reviewed.Methods for preserving the phenotype of primary human hepatocytes have been successfully developed. Many genetically engineered cell lines and immortalized human hepatocytes have also been established. Among these cell lines, the incorporation of BAL with GS-HepG2 cells or alginate-encapsulated HepG2 cells could prolong the survival time and improve pathophysiological parameters in an animal model of liver failure. The cBAL111 cells were evaluated using the AMC-BAL bioreactor, which could eliminate ammonia and lidocaine, and produce albumin. Importantly, BAL loading with HepLi-4 cells could significantly improve the blood biochemical parameters, and prolong the survival time in pigs with liver failure. Other functional hepatocytes differentiated from stem cells, such as human liver progenitor cells, have been successfully achieved.Aside from genetically modified liver cell lines and immortalized human hepatocytes, other functional hepatocytes derived from stem cells show great potential as cell sources for BAL. BAL with safe and effective liver cells may be achieved for clinical liver failure in the near future.
-
Configuration of a new bioartificial liver support system and in vitro evaluation of its functions.
Zhong Chen,Yitao Ding,Genxi Li
2005-01-01
Annals of clinical and laboratory science
Abstract:The aim of this study was to configure a new bioartificial liver (BAL) support system and evaluate its functions in vitro. Chinese experimental miniature pig hepatocytes were isolated by an in situ recirculating collagenase perfusion method and were cultured in serum-free medium with restriction attachment and spinner technique to form hepatocyte spheroid suspensions containing 1.0 x 10(10) hepatocytes. The BAL support system was configured by inoculating the hepatocyte spheroids into the cell circuit of a hollow fiber bloreactor (BIOLIV A3A, Cell Biotech Limited, HK, China). The number and viability of hepatocytes, the levels of alanine aminotransferase (ALT), total bilirubin (TBi), and albumin (ALB) in the circulating hepatocyte suspension and RPMI-1640 medium, and lidocaine metabolism were determined during 6 hr of circulation in the BAL devices. Independent experiments were performed 5 times. There were no significant changes in the number and viability of the hepatocytes during the circulation period. The BAL support system demonstrated substantial albumin synthesis and lidocaine metabolism. The results indicate that the new BAL support system has the ability to perform liver functions and Could be used to treat liver failure or provide temporary liver support in patients who are candidates for liver transplantation.
-
Experimental study of bioartificial liver with cultured human liver cells.
Ying-Jie Wang,Meng-Dong Li,Yu-Ming Wang,Qing-He Nie,Guo-Zheng Chen
DOI: https://doi.org/10.3748/wjg.v5.i2.135
IF: 5.374
1999-01-01
World Journal of Gastroenterology
Abstract:AIM To establish an extracorporeal bioartificial liver support system (EBLSS) using cultured human liver cells and to study its support effect for fulminant hepatic failure (FHF). METHODS The liver support experiment of EBLSS consisting of aggregates cultured human liver cells, hollow fiber bioreactor, and circulation unit was carried out in dizhepatic dogs. RESULTS The viability of isolated hepatocytes and nonparenchymal liver cells reached 96%. These cells were successfully cultured as multicellular spheroids with synthetic technique. The typical morphological appearance was retained up to the end of the artificial liver experiment. Compared with the control dogs treated with EBLSS without liver cells, the survival time of artificial liver support dogs was significantly prolonged. The changes of blood pressure, heart rate and ECG were slow. Both serum ammonia and lactate levels were significantly lowered at the 3rd h and 5th h. In addition, a goad viability of human liver cells was noted after 5 h experiment. CONCLUSION EBLSS playing a metabolic role of cultured human hepatocytes, is capable of compensating the function of the liver, and could provide effective artificial liver support and therapy for patients with FHF.
-
The Development of a New Bioartificial Liver and Its Application in 12 Acute Liver Failure Patients
YT Ding,YD Qiu,Z Chen,QX Xu,HY Zhang,Q Tang,DC Yu
DOI: https://doi.org/10.3748/wjg.v9.i4.829
2003-01-01
Abstract:AIM: Bioartificial liver is a hope of supporting liver functions in acute liver failure patients. Using polysulfon fibers, a new bioartificial liver was developed. The aim of this study was to show whether this bioartificial liver could support liver functions or not.METHODS: Hepatocytes were procured from swine using Seglen's methods. The bioartificial liver was constructed by polysulfon bioreactor and more than 10(10) hepatocytes. It was applied 14 times in 12 patients, who were divided into 7 cases of simultaneous HEAL and 5 cases of non-simultaneous HBAL. Each BAL treatment lasted 6 hours. The general condition of the patients and the biochemical indexes were studied.RESULTS: After treatment with bioartificial liver, blood ammonia, prothrombin time and total bilirubin showed significant decrease. 2 days later, blood ammonia still showed improvment. within one month period, 1 case (1/7) in simultaneous group died while in non-simultaneous group 2 cases (2/5) died. The difference was significant. Mortality rate was 25%.CONCLUSION: The constructed bioartificial liver can support liver functions in acute liver failure. The simultaneous HBAL is better than non-simultaneous HBAL.
-
Evaluation of a Novel Hybrid Bioartificial Liver Based on Multi-Layer Fiat-Plate Bioreactor
SHI Xiao-lei,ZHANG Yue,CHU Xue-hui,GU Jin-yang,HAN Bing,DING Yi-tao
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2012.05.032
2012-01-01
Abstract:Objective To evaluate the efficacy of a novel hybrid bioartificial liver based on multilayer flat-plate bioreactor in treatment of acute liver failure.Methods The animals were divided into the hybrid bioartificial liver (HBAL) treatment group (n =8 ),the bioartificial liver (BAL) treatment group (n =8),the non-bioartificial liver (NBAL) treatment group (n =8),and the control group (n =8).Biochemical parameters and survival time were determinedt.The levels of xenoantibodies ( IgG,IgM) were determined by using enzyme linked immunosorbent assay ( ELISA ).The PERV mRNA expression in the plasma was detected by using reverse transcription-polymerase chain reaction (RT-PCR).Results Biochemical parameters were significantly decreased in all treatment groups. Analysis of survival curves showed that the 7-day survival rate was 37.5％ (3/8) in the control group,50.0％ (4/8) in the NBAL group,62.5％ (5/8) in the BAL group and 87.5％ (7/8) in the HBAL group respectively.Survival time was significantly prolonged by HBAL treatment ( P ＜ 0.05 ).Conclusion The hybrid bioartificial liver showed a great efficiency in the treatment of acute liver failure.
-
Bioartificial liver inoculated with porcine hepatocyte spheroids for treatment of canine acute liver failure model.
Zhong Chen,Yitao Ding,Qingxiang Xu,Decai Yu
DOI: https://doi.org/10.1046/j.1525-1594.2003.07140.x
2003-01-01
Artificial Organs
Abstract:The aim of this study was to evaluate a novel bioartificial system in a canine model of acute liver failure. An acute liver failure model in canines was induced by an end-side portocaval shunt combined with common bile duct ligation and transection. The bioartificial liver system, which utilized blood perfusion through a hollow fiber bioreactor from BIOLIV A3A inoculated with 1.0 - 3.1 x 10(10) porcine hepatocyte spheroids, was developed for the treatment of acute liver failure. Sixteen acute liver failure model canines were divided between a group treated with bioartificial liver (n=8) and a control group (n=8) for 5 h. Blood alanine aminotransferase (ALT), alkaline phosphatase (AKP), total bilirubin (TBi), direct bilirubin (DBi), prothrombin time (PT), ammonia levels, and the ratio of branched chain to aromatic amino acids (Fischer's ratio) were determined. ALT, AKP, TBi, DBi, and ammonia levels were significantly elevated, PT was significantly prolonged, and Fischer's ratio decreased significantly in the canine model of the two groups on day 14 after operation compared to baseline. There were no significant differences between the two groups in laboratory data before treatment. In canines treated with the bioartificial liver system, ALT, AKP, TBi, DBi, and ammonia levels decreased significantly, PT was significantly shortened, Fischer's ratio was significantly elevated after treatment, and the survival rate by day 7 after treatment was 100%. In canines in the control group, on the other hand, there were no significant differences in ALT, AKP, TBi, DBi, PT, and ammonia levels between pretreatment and posttreatment, though these indices decreased to a slight degree after treatment. The survival rate by day 7 after treatment was 62.5% in the control group. Fischer's ratio decreased after treatment. ALT, AKP, TBi, DBi, PT, and ammonia levels in the bioartificial liver system group were lower, and Fischer's ratio and survival rate were higher than those in the control group after treatment. These results indicate that the novel bioartificial liver system we developed has a significant impact on the course of canine acute liver failure model and has potential advantages for clinical use in patients with acute liver failure.
-
Establishment of gene‐edited pigs expressing human blood‐coagulation factor VII and albumin for bioartificial liver use
Li Li,Hongyi Meng,Qingjian Zou,Jianmin Zhang,Lei Cai,Bin Yang,Jun Weng,Liangxue Lai,Huaqiang Yang,Yi Gao
DOI: https://doi.org/10.1111/jgh.14666
2019-04-10
Journal of Gastroenterology and Hepatology
Abstract:Bioartificial livers (BALs) are considered as a solution to bridge patients with acute liver failure to liver transplantation or to assist in spontaneous recovery for patients with end‐stage liver disease. Pig is the best donor of hepatocytes for BALs in clinical trials, because metabolic and detoxification function of its liver are close to human. However, using pig hepatocytes for BALs remains controversial for safety concern owing to nonhuman proteins secretion. Herein, we attempt to establish modified pigs expressing humanized liver proteins, blood coagulation factor VII (F7) and albumin (ALB). These pigs should also be porcine endogenous retrovirus subtype C (PERV‐C) free so that their ability of transmitting PERV to human could be diminished seriously.We devised both homology‐dependent and independent knock‐in approaches to insert a fusion of <i>hF7</i> and <i>hALB</i> gene downstream the site of pig endogenous <i>F7</i> promoter in pig fetal fibroblasts negative for PERV‐C. The modified pigs were then generated through somatic cell nuclear transfer. We obtained 14 and 10 cloned pigs by homology‐dependent and independent approaches, respectively. Among them, 19 cloned pigs were with expected gene modification and 13 are alive to date. These modified pigs can successfully express hF7 and hALB in the liver and serum, and the expressed hF7 exhibits normal coagulation activity.The gene‐edited pigs expressing hF7 and hALB in the liver were generated successfully. We anticipate that our pigs could provide an alternative cell source for BALs as a promising treatment for patients with acute liver failure.
gastroenterology & hepatology